Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

University of Oxford: Clinical Trials & FDA Approval Profile

University of Oxford (Global / Institutional) sponsors 67 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 22 active protocols (8 recruiting now), 32 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)10.4%
Median Closed Enrollment vs National (145 pts)86 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for University of Oxford
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)67
Active Pipeline (Recruiting Now)22 (8)
Completed vs Stopped Early32 / 7 (10.4%)
Median Closed Actual Enrollment86 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With University of Oxford
Hospital Research SiteLocationShared Protocols
University Hospital Southampton NHS Foundation TrustSouthampton, Hampshire5
John Radcliffe HospitalOxford5
Imperial College Healthcare NHS TrustLondon3

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by University of Oxford
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT04400838Investigating a Vaccine Against COVID-19Phase II/IIICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the University of Oxford Interactive Dossier, benchmark peers in Infectious Disease and Vaccines, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI